

Subscription price for the exercise of warrants of series T07 in Lumito AB has been set at 3.5 SEK per share, and the exercise period begins today, 25 May 2026

Lumito AB (publ) ("Lumito" or the "Company") issued warrants of series T07 in connection with a rights issue during the fourth quarter of 2025. Five hundred (500) warrants entitle the holder to subscribe for one (1) new share in the Company. The subscription price for the warrants of series T07 was set at 70 percent of the volume-weighted average price of the Company's share on NGM Growth Market during the measurement period from 7 May 2026 up to and including 21 May 2026, however not lower than the quota value of the Company's shares and not higher than SEK 15.50 per share. The discounted volume-weighted average price of the Company's share during the measurement period amounted to approximately 2.09 SEK. The subscription price has therefore been set at the share's quota value of 3.5 SEK. The exercise period for warrants of series T07 runs from 25 May 2026 up to and including 5 June 2026.

Complete terms and conditions for the warrants are available on the Company's website, www.lumito.se/en/.

Summary terms for the warrants of series T07:

Exercise period: 25 May 2026 – 5 June 2026.

Subscription price: 3.5 SEK per share.

Issue volume: Five hundred (500) warrants of series T07 entitling the holder to subscribe for 1 new share. Upon full exercise of all warrants of series T07, the Company may receive up to approximately 6.7 MSEK before issue costs.

Last day of trading in warrants of series T07: 2 June 2026.

Dilution: Upon full exercise of all warrants of series T07, the number of shares in the Company will increase by up to 1,914,466 from 3,440,897 shares to a maximum of 5,355,363 shares and the share capital by up to 6,700,631 SEK from 12,043,139.5 SEK to a maximum of 18,743,770.5 SEK, corresponding to a maximum dilution effect of approximately 35.7 percent of the number of shares.

Please note that warrants that are neither sold by 2 June 2026 nor exercised by 5 June 2026 will expire worthless. In order for warrants of series T07 not to expire, warrant holders must actively subscribe for shares or alternatively sell the warrants. Please note that certain nominees may close their application earlier than 5 June 2026.

How the warrants are exercised:

Nominee-registered warrants (custody account):

Subscription and payment through exercise of warrants shall take place in accordance with instructions from the respective nominee. Please contact your nominee for further information.

Directly registered warrants (VP account):

No issue statement or payment instructions will be sent out. Subscription shall take place through simultaneous cash payment in accordance with the instructions on the application form. The warrants will thereafter be replaced with interim shares (IA) pending registration with the Swedish Companies Registration Office.

An application form with payment instructions will be available on the Company's website, www.lumito.se/en/.

Advisers

Mangold Fondkommission AB is financial adviser and Advokatfirman Lindahl KB is legal adviser to Lumito in connection with the exercise of warrants of series T07.

For further information, please contact:

Sanna Wallenborg, CEO Lumito

E-mail: sw@lumito.se

Ph: +4670-870 01 68

About Lumito

Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments

[Subscription price for the exercise of warrants of series T07 in Lumito AB has been set at 3.5 SEK per share, and the exercise period begins today, 25 May 2026](#)